- Home
- PENN vs AUPH Comparison
PENN vs AUPH Comparison
Compare PENN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENN | AUPH |
|---|---|---|
| Founded | 1972 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PENN | AUPH |
|---|---|---|
| Price | $19.23 | $15.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $20.83 | $17.25 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $6,362,900,000.00 | $283,055,000.00 |
| Revenue This Year | $6.85 | $17.54 |
| Revenue Next Year | $3.83 | $15.74 |
| P/E Ratio | ★ N/A | $66.00 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $11.65 | $7.29 |
| 52 Week High | $20.61 | $16.88 |
Technical Indicators
Market Signals| Indicator | PENN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 54.94 |
| Support Level | $18.67 | $14.53 |
| Resistance Level | $20.32 | $16.29 |
| Average True Range (ATR) | 0.78 | 0.54 |
| MACD | 0.20 | 0.07 |
| Stochastic Oscillator | 71.57 | 60.52 |
Price Performance
Historical ComparisonAbout PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.